- Home
- SNTI
as 11-03-2025 4:00pm EST
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 53.6M | IPO Year: | N/A |
| Target Price: | $9.67 | AVG Volume (30 days): | 292.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $16.94 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.00% |
Latest Senti Biosciences Inc. News
SNTI Breaking Stock News: Dive into SNTI Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 hours ago
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire
19 days ago
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
MT Newswires
21 days ago
HC Wainwright Initiates Coverage on Senti Biosciences With Buy Rating, $12 Price Target
GlobeNewswire
a month ago
Senti Bio to Present at BioJapan
GlobeNewswire
4 months ago
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
MT Newswires
5 months ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
GlobeNewswire
5 months ago
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
GlobeNewswire
5 months ago
Senti Biosciences Announces New Employment Inducement Grants
Compare SNTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNTI Senti Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.